Last reviewed · How we verify
HDM1005 1
HDM1005 1 is a small molecule drug.
HDM1005 1 is a small molecule drug. Used for phase_3.
At a glance
| Generic name | HDM1005 1 |
|---|---|
| Sponsor | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Unfortunately, I do not have information on the specific mechanism of action of HDM1005 1.
Approved indications
- phase_3
Common side effects
Key clinical trials
- A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor (PHASE3)
- A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone (PHASE3)
- Phase Ib Clinical Study of HDM1005 Injection (PHASE1)
- Phase Ia Clinical Study of HDM1005 Injection (PHASE1)
- Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes (PHASE3)
- Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus (PHASE2)
- A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |